Ethnic difference in contribution of alleles of the interleukin‐1 receptor antagonist gene to predisposition to osteoporosis
暂无分享,去创建一个
Y. Ouchi | S. Inoue | M. Emi | H. Orimo | M. Shiraki | T. Hosoi | S. Ogawa | Hiroaki Sugiyama
[1] D. Crossman,et al. Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[2] E. Eriksen,et al. Osteoporotic Fractures Are Associated with an 86‐Base Pair Repeat Polymorphism in the Interleukin‐1‐Receptor Antagonist Gene But Not with Polymorphisms in the Interleukin‐1β Gene , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] T. Nakajima,et al. Ethnic Difference in Contribution of Sp1 Site Variation of COLIA1 Gene in Genetic Predisposition to Osteoporosis , 1999, Calcified Tissue International.
[4] T. Spector,et al. Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. , 1998, Bone.
[5] M. Emi,et al. Isolation and mapping of a polymorphic CA repeat sequence at the human interleukin 6 locus , 1998, Journal of Human Genetics.
[6] S. Grant,et al. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I α 1 gene , 1996, Nature Genetics.
[7] Y. Ouchi,et al. Association of bone mineral density with polymorphism of the estrogen receptor gene , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] T. Spector,et al. Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: a twin study in Britain , 1995, BMJ.
[9] D. Grennan,et al. Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1Ra) gene polymorphism , 1995, Clinical and experimental immunology.
[10] A. Steinkasserer,et al. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. , 1994, Journal of immunology.
[11] J. Eisman,et al. Prediction of bone density from vitamin D receptor alleles , 1994, Nature.
[12] G. Passeri,et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. , 1993, Endocrinology.
[13] A. Blakemore,et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat , 1993, Human Genetics.
[14] S. Cummings,et al. Bone density at various sites for prediction of hip fractures , 1993, The Lancet.
[15] T. Linkhart,et al. Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism. , 1992, Endocrinology.
[16] D. Sheer,et al. Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene. , 1992, Cytokine.
[17] S. Haskill,et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Hopper,et al. Reduced bone mass in daughters of women with osteoporosis. , 1989, The New England journal of medicine.
[19] J. Hopper,et al. Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.